Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX17 Capmatinib
D10891 Capmatinib hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
MET Inhibitors
Capmatinib
D10891 Capmatinib hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10891 Capmatinib hydrochloride (USAN); Capmatinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG02081 Capmatinib
D10891 Capmatinib hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02081 Capmatinib
D10891 Capmatinib hydrochloride
DG02953 AOX1 substrate
DG02081 Capmatinib
D10891 Capmatinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
MET family
MET* [HSA_VAR:4233v4]
D10891 Capmatinib hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10891
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10891
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10891
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10891
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10891
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG02081 Capmatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02081 Capmatinib
DG02953 AOX1 substrate
DG02081 Capmatinib